|
JAMA Oncology |
Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma - A Review |
1 |
Yes |
8/3/2025 |
|
JAMA Oncology |
Endometrial Cancer Classification and Management in the Molecular Subtyping Era |
1 |
Yes |
10/10/2027 |
|
JAMA Oncology |
Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant |
1 |
Yes |
4/22/2025 |
|
JAMA Oncology |
Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant |
1 |
Yes |
4/22/2025 |
|
JAMA Oncology |
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease |
1 |
Yes |
4/21/2025 |
|
JAMA Oncology |
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease |
1 |
Yes |
4/21/2025 |
|
JAMA Oncology |
Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers - A Systematic Review |
1 |
Yes |
8/29/2027 |
|
JAMA Oncology |
Global Association of COVID-19 Pandemic Measures With Cancer Screening - A Systematic Review and Meta-analysis |
1 |
Yes |
8/1/2025 |
|
JAMA Oncology |
Global Association of COVID-19 Pandemic Measures With Cancer Screening- A Systematic Review and Meta-analysis |
1 |
Yes |
8/1/2025 |
|
JAMA Oncology |
Hairy Kidneys and Sclerotic Bone Lesions |
1 |
Yes |
10/24/2027 |
|
JAMA Oncology |
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer - A Review |
1 |
Yes |
9/12/2027 |
|
JAMA Oncology |
Identification of Deaths Caused by Cancer and COVID-19 in the US During March to December 2020 |
1 |
Yes |
10/26/2025 |
|
JAMA Oncology |
Identification of Deaths Caused by Cancer and COVID-19 in the US During March to December 2020 |
1 |
Yes |
10/26/2025 |
|
JAMA Oncology |
Immunotherapy in the Treatment of Localized Genitourinary Cancers |
1 |
Yes |
8/10/2026 |
|
JAMA Oncology |
Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer |
1 |
Yes |
9/23/2025 |
|
JAMA Oncology |
Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer |
1 |
Yes |
9/23/2025 |
|
JAMA Oncology |
Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer - The FAST Multidisciplinary Group Consensus Statement |
1 |
Yes |
7/11/2027 |
|
JAMA Oncology |
Left Axilla Adenocarcinoma of Unknown Origin |
1 |
Yes |
3/16/2026 |
|
JAMA Oncology |
Left Shoulder Fungating Mass in a 46-Year-Old Man |
1 |
Yes |
6/15/2026 |
|
JAMA Oncology |
Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors |
1 |
Yes |
4/22/2025 |
